MicroPulse P3^® Delivery Device

Versatile and Non-Incisional Glaucoma Treatment With MicroPulse® Transscleral Laser Therapy

A success rate of 60% to 80%^1-17
Achieves IOP reduction of 30% to 45%^{1, 3, 6, 9-15, 17, 18}
Durability of up to 72 months with 3 retreatments¹⁹
Over 120,000 patients treated in 60 countries
Leaves future treatment options open

Re-Thinking Glaucoma Care
MICROPULSE® TRANSSCLERAL LASER THERAPY (TLT)

A cost-effective combination of safety, efficacy, durability and repeatability in a non-incisional approach to glaucoma care. MicroPulse Transscleral Laser Therapy via the MicroPulse P3® Device offers you and your patients a therapy which can be introduced prior to, in conjunction with and following all other available glaucoma treatment options, and the ability to treat at several different time points throughout the course of the disease.

A success rate of 60% to 80%^1-17
Leaves future treatment options open
Achieves IOP reduction of 30% to 45%^{1, 3, 6, 9-15, 17, 18}
Durability of up to 72 months with 3 retreatments¹⁹
Used in 38 of the 39 best hospitals in the United States*
Reduction in drug burden in eye drops and oral medications^{1-4, 6-13, 18}
Revised probe now available with improved ease of use, visualization, fit, and coupling
Limited amount of immediate follow-up
Patient downtime is significantly low
Low investment for high utility
Economic savings to patients

1 Zaarour K, et al. J Glaucoma 2019. 2 Subramaniam K, et al. Cornea 2019. 3 Nguyen AT, et al. Eur J Ophthalmol 2019. 4 Barac R, et a. Romanian J Ophthalmol 2018. 5 Sanchez FG, et al. Arch Soc Esp Oftalmol 2018. 6 Lee JH, et al. J Glaucoma 2017. 7 Sarrafpour S, et al. Ophthalmology Glaucoma 2019. 8 Awoyesuku EA, et al. JAMMR 2019. 9 Abdelrahman AM, et al. J Glaucoma 2018. 10 Aquino MC, et al. Clin Exp Ophthalmol 2015. 11 Jammal AA, et al. Arq Bras Oftalmol 2019. 12 Tan A, et al. Clin Experiment Ophthalmol 2010. 13 Williams AL, et al. J Glaucoma 2018. 14 Varikuti VNV, et al. J Glaucoma 2019. 15 Souissi S, et al. Eur J Ophthalmol 2019. 16 Magacho L, et al. Lasers Med Sci 2019. 17 Magacho L, et al. J Glaucoma 2019. 18 Yelenskiy A, et al. J Glaucoma 2018. 19 Aquino M, et al. European Glaucoma Society 2016. * As ranked by U.S. News and World Report.

    A viscous, liquid interface (e.g. methyl cellulose) must be utilized to ensure proper light coupling to the conjunctiva. Place a drop on the undersurface of the probe footplate. Reapply as necessary. Not using a liquid interface could result in loss of up to 40% of energy.
    Orient the probe with the wide, curved side (bunny ears) aligned at the surgical limbus to ensure consistent treatment application. Be sure to view from directly above to avoid placement error because of parallax.
    Maintain the footplate of the probe flat against the conjunctiva throughout the treatment with constant, gentle pressure. Do not rock the probe while sweeping.
    Use 2500 mW, 50 seconds per hemisphere, and a duty cycle of 31.3%.
    Sweep the probe along the limbus in an arc of 150 degrees for 10 seconds (avoid the 3 and 9 o’clock positions). Maintain a constant velocity during each pass.
    Reverse the direction and repeat for a total of 5 passes.

Technique Instructions

    Apply a liquid viscous interface to the bottom of the delivery device footplate and/or the eye to be treated. This is a mandatory requirement.
    Orient the probe with the wide, curved side (bunny ears) aligned at the surgical limbus to ensure consistent treatment application. Holding the delivery device with the tips of your fingers allows you to rotate the probe as you sweep to keep the orientation aligned with the limbus throughout the procedure.
    Keep the scleral-matching curvature flat and flush with the sclera throughout the procedure. It is important that you do not rock probe and keep full contact throughout the procedure.
    Remember to avoid the 3 and 9 o’clock positions when treating.
    The tapered stem can be used as your speculum if need be in very tight orbits.
    The recommended power for MicroPulse TLT is 2500 mW.
    The constants for MicroPulse TLT are 50 seconds per hemisphere (25 seconds per quadrant) and five passes per duration. Ten seconds per pass for hemisphere (five seconds per pass per quadrant). The duty cycle for is 31.3%.
    Standard post-operative medication regimen is steroid drops QID x 1 week and then BID x 1 week. Cycloplegia is not required following MicroPulse TLT.